Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose NMN for aging-related outcomes in older adults
jRCTs031220373Completed
- Sponsor
- Mirailab Bioscience
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in Senility and presbycusis comparing NMN 1,250 mg with Placebo (2 arms). Primary endpoint: Change in hearing ability. Started Oct 2022; status: completed.
02
Drugs
nicotinamide mononucleotide
03
Conditions
Senilitypresbycusis
Beyond the preview
Go deeper on jRCTs031220373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220373.